1. Qatar Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Qatari German Company for Medical Devices (Q.P.S.C.)

Qatari German Company for Medical Devices (Q.P.S.C.)

QGMD.QA
Qatari German Company for Medical Devices (Q.P.S.C.)QA flagQatar Stock Exchange
1.33
QAR
+0.01
- -
153.85MMarket Cap
Qatari German Company for Medical Devices (Q.P.S.C.)
QGMD.QA
(Qatar Stock Exchange)

Recent

price

1.33

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.07
0.07
0.12
0.1
0.14
0.14
0.11
0.1
0.1
0.07
0.21
0.35
0.37
0.24
0.09
0.04
0.04
Revenue per Share
-0.03
- -
-0.04
-0.08
-0.12
-0.1
-0.09
-0.19
-0.11
-0.09
0.01
0.01
0.01
0.01
-0.59
0.08
0.09
Basic EPS, GAAP
-0.04
-0.2
-0.21
-0.14
-0.19
-0.08
-0.01
-0.01
-0.01
0.02
-0.14
0.05
0.01
-0.02
0.01
0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.02
1.01
0.98
0.74
0.48
0.38
0.29
0.1
-0.01
-0.1
-0.09
-0.09
-0.07
-0.06
-0.65
-0.58
-0.59
Book Value per Share
1.48
1.4
1.36
0.86
0.75
0.65
0.56
0.38
0.27
0.18
0.18
0.19
0.21
0.22
-0.37
-0.27
-0.28
Tangible Book Value per Share
116
116
116
116
116
116
116
116
116
116
116
116
116
116
116
116
115
Basic Weighted Avg Shares
8
8
14
11
16
16
13
12
11
8
25
41
43
28
10
5
5
Sales/Revenue/Turnover
-29.38
-66.32
-40.07
-101.43
-75.13
-52.01
-46.79
-110.16
-88.01
-115.68
-11.74
8.95
6.35
-3.44
-600.78
-166.65
-142.89
Operating Margin (%)
2
2
2
3
3
3
3
3
6
6
5
5
5
5
5
5
5
Depreciation Expense
-3
- -
-5
-9
-13
-11
-10
-22
-13
-10
1
1
1
1
-68
9
10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-42.58
5.18
-33.82
-82.12
-84.2
-69.61
-81.86
-183.81
-112.55
-127.3
3.6
2.91
2.92
4.8
-685.92
202.82
216.27
Profit Margin (%)
14
11
7
-1
-21
-29
-2
-21
-4
-8
-9
-23
-1
-80
-141
-3
-4
Working Capital
17
19
32
37
38
46
81
74
99
100
98
78
93
11
13
136
135
LT Debt
201
190
185
128
97
86
76
54
41
31
32
33
34
36
-32
-23
-24
Total Equity
-1.04
-2.33
- -
- -
- -
- -
- -
- -
- -
- -
-1.86
2.15
1.56
-0.55
- -
-11.05
-5.83
Return on Invested Capital (%)
-1.72
0.98
- -
- -
- -
- -
- -
- -
- -
- -
3.03
4.5
3.74
2.97
- -
14.52
16.06
Return on Capital (%)
-2.8
0.33
-4.05
-9.45
-18.92
-23.17
-27.01
-96.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
6
6
6
LT Borrowings
135
136
135
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
116
116
116
Market Capitalization
200
169
153

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
19
18
18
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
4
1
3
Inventories
16
15
15
Total Current Liabilities
30
22
22
Payables & Accruals
- -
- -
- -
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-29.13%
-40.84%
-27.87%
Free Cash Flow
-194.18%
-138.45%
29.08%
Net Income, GAAP
-536.2%
-1,058.7%
-113.54%
Sales/Revenue/Turnover
5.68%
-16.56%
-54.2%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
2
2
1
10
2025
1
1
1
2
5
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.59
2025
-0.01
- -
- -
- -
0.08
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Ttbio Corp. (6493.TWO)
Reflect Scientific, Inc. (RSCF)
Gan & Lee Pharmaceuticals. (603087.SS)
Kangji Medical Holdings Limited (9997.HK)
Zentek Ltd. (ZEN.V)
NanoString Technologies, Inc. (NSTGQ)
Business
Qatari German Company for Medical Devices (Q.P.S.C.) (QGMD.QA) manufactures and sells single-use disposable medical syringes and related devices in Qatar and internationally; trades in medical consumables, equipment, tools, supplies and furniture; and provides healthcare training services. Its core products include Q JectUltra insulin syringes for diabetic care; Q Flow IV cannulas for infusion therapy; Q Need single-use hypodermic needles; Q Ject single-use syringes for curative medications; and Q Safe re-use prevention syringes, all produced in a state-of-the-art facility in Doha designed by technology providers from Germany, Switzerland and Italy. Founded in 2000 and headquartered in Abu Hamour, Doha, Qatar, the company operates primarily in the Middle East with growing exports to Europe and other regulated markets, serving healthcare providers, hospitals and pharmacies. In 2024, QGMD expanded its commercial activities by launching a new business line to distribute medical consumables and first aid supplies through hypermarkets, pharmacies and gas stations in Qatar; participated in the Qatar-South Korea trade mission organized by Qatar Development Bank to enhance global market access; and appointed Amer Abu Shaikha as a key executive while hosting visits from high-level officials including His Excellency Sheikh Mohammed bin Hamad bin Qassim Al Abdullah Al Thani. The company continues to pursue strategic growth amid reported financial challenges, including a QR68.485 million net loss in 2024.